Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292746 | 0.92 | NPC1 (0.40) | HTR7TMEM97SIGMAR1HTR1ANPC1 | |
| SCHEMBL4292346 | 0.91 | BDKRB1 (0.34) | HTR7TMEM97SIGMAR1NPC1BDKRB1 | |
| SCHEMBL4300839 | 0.91 | BDKRB1 (0.41) | HTR7TMEM97SIGMAR1BDKRB1 | |
| SCHEMBL4299091 | 0.90 | ALDH1A1 (0.35) | HTR7HTR1A | |
| SCHEMBL3441641 | 0.89 | BDKRB1 (0.39) | HTR7BDKRB1 | |
| SCHEMBL3441640 | 0.89 | BDKRB1 (0.39) | HTR7BDKRB1 | |
| SCHEMBL3441912 | 0.89 | DRD2 (0.37) | HTR7TMEM97SIGMAR1BDKRB1TDP1 | |
| SCHEMBL3443457 | 0.88 | HTR7 (0.35) | HTR7TMEM97SIGMAR1NPC1BDKRB1 | |
| SCHEMBL4302599 | 0.88 | BDKRB1 (0.35) | HTR7TMEM97SIGMAR1NPC1BDKRB1 | |
| SCHEMBL3441475 | 0.86 | HTR7 (0.40) | HTR7TMEM97SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | HTR7 939/4885TMEM97 764/4885SIGMAR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.